This retrospective analysis compared standard regimen of doxorubicin, bleomycin, vin- blastine, and dacarbazine （ABVD） with the dose-dense ABVD regimen （ABVD-21） in terms of effi- cacy and toxicity. Patients who h...This retrospective analysis compared standard regimen of doxorubicin, bleomycin, vin- blastine, and dacarbazine （ABVD） with the dose-dense ABVD regimen （ABVD-21） in terms of effi- cacy and toxicity. Patients who had early-stage unfavorable or advanced Hodgkin＇s lymphoma （HL） according to German Hodgkin Study Group criteria from March 1999 to February 2011 were ana- lyzed for treatment response, long-term survival and hematological toxicity. There were 85 patients in the ABVD-21 group and 118 patients in the ABVD group respectively. The complete remission rates aider completion of treatment were 92.9% and 90.7% for ABVD-21 and ABVD, respectively. During a median follow-up period of 62 months, no significant difference was found in projected 10-year progression-free survival （PFS） and overall survival （OS） rates （84.7% and 94.1% respectively for ABVD-21; 81.4% and 91.5% for ABVD）. Subgroup analyses showed that ABVD-21 was signifi- cantly better than ABVD for patients with IPS〉3 in terms of PFS and OS rates. Grade 3 to 4 leuko- penia （51.8% vs. 28.8%, P=0.001） and neutropenia （57.6% vs. 39.0%, P=0.009） were more common with ABVD-21. We were led to conclude that dose-dense ABVD did not result in better tumor con- trol and overall survival than did ABVD for early-stage unfavorable HL. However, patients at high risk, for example, with IPS〉3, may benefit from dose-dense ABVD.展开更多
Chemotherapy with continuous infusion of 5-fluorouracil and cisplatin in a monthly schedule is one of the most common regimens in the treatment of advanced gastric cancer. In this study, we evaluated the efficacy and ...Chemotherapy with continuous infusion of 5-fluorouracil and cisplatin in a monthly schedule is one of the most common regimens in the treatment of advanced gastric cancer. In this study, we evaluated the efficacy and safety of a dosedense administration of this regimen in this patient population. Sixty-six consecutive patients with previously untreated histologically confirmed unresectable or metastatic gastric adenocarcinoma were treated with a 2-hour infusion of cisplatin 100 mg/m2 followed by continuous infusion of 5-fluorouracil 1000 mg/m2/day for 5 days, every 21 days. The most common grade ≥3 toxicities were fatigue (42%), nausea/vomiting (30%) and leucopenia (12%). Four patients (6%) died from treatment-related toxicity. The response rate was 35%, the median progression-free survival was 4.3 months and the median survival was 5.9 months. In light of these results, the dose-dense approach seems to offer little, if any, benefit compared with the standard regimens.展开更多
The hot dense nuclear matter is studied in the chiral σ-ω model in theformalism of thermo-field dynamics.The binding energy,pressure and effective mass ofnucleon are calculated in the level of one-loop vaccum quantu...The hot dense nuclear matter is studied in the chiral σ-ω model in theformalism of thermo-field dynamics.The binding energy,pressure and effective mass ofnucleon are calculated in the level of one-loop vaccum quantum fluctuation.The tem-perature effect is found very large at high temperature and the pressure can not reachsaturation as a function of nuclear density.展开更多
We study a general framework for assessing the injury probability corresponding to an input dose quantity. In many applications, the true value of input dose may not be directly measurable. Instead, the input dose is ...We study a general framework for assessing the injury probability corresponding to an input dose quantity. In many applications, the true value of input dose may not be directly measurable. Instead, the input dose is estimated from measurable/controllable quantities via numerical simulations using assumed representative parameter values. We aim at developing a simple modeling framework for accommodating all uncertainties, including the discrepancy between the estimated input dose and the true input dose. We first interpret the widely used logistic dose-injury model as the result of dose propagation uncertainty from input dose to target dose at the active site for injury where the binary outcome is completely determined by the target dose. We specify the symmetric logistic dose-injury function using two shape parameters: the median injury dose and the 10 - 90 percentile width. We relate the two shape parameters of injury function to the mean and standard deviation of the dose propagation uncertainty. We find 1) a larger total uncertainty will spread more the dose-response function, increasing the 10 - 90 percentile width and 2) a systematic over-estimate of the input dose will shift the injury probability toward the right along the estimated input dose. This framework provides a way of revising an established injury model for a particular test population to predict the injury model for a new population with different distributions of parameters that affect the dose propagation and dose estimation. In addition to modeling dose propagation uncertainty, we propose a new 3-parameter model to include the skewness of injury function. The proposed 3-parameter function form is based on shifted log-normal distribution of dose propagation uncertainty and is approximately invariant when other uncertainties are added. The proposed 3-parameter function form provides a framework for extending skewed injury model from a test population to a target population in application.展开更多
A computer program MACA was developed for simulating high-dose ion implantation into amorphous solids. The topology of amorphous solids was modelled by adjusting the free flight path distribution between collisions, s...A computer program MACA was developed for simulating high-dose ion implantation into amorphous solids. The topology of amorphous solids was modelled by adjusting the free flight path distribution between collisions, so that the radial distribution function will characterize the short - range order and long - range disorder of amorphous targets. A simulation example is given.展开更多
Three different kinds of corundum aggregates-tabular sintered alumina, dense sintered alumina, and fused dense corundum-were introduced into the silica fume .free or silica fume containing Al2O3 -SiC - C iron runner c...Three different kinds of corundum aggregates-tabular sintered alumina, dense sintered alumina, and fused dense corundum-were introduced into the silica fume .free or silica fume containing Al2O3 -SiC - C iron runner castables to investigate their influences on the flow ability, linear change on heating, bulk density, apparent porosity, cold strength, hot modulus of rupture, therm, al shock resistance, slag resistance, oxidation resistance as well as wear resistance of Al2O3 - SiC - C iron runner castables. The results show that （ 1 ） compared with the specimens with fused dense corundum, the specimens with dense sintered alumina have equivalent installation property, slag resistance and oxidation resistance, equivalent or even higher cold modulus of rupture, cold crushing strength and hot modulus of rupture, exhibiting better thermal shock resistance and cold wear resistance ; （2） adopting bimodal alumina micropowder LISAL22RABL as well as water reducers ZX2 and ZD2 can well reduce the water requirement of silica fume free castables, solving the problem of deteriorated flow ability resulted from the lack of silica fume; since the lack of silica fume avoids the formation of low melting point liquid, the hot modulus of rupture and the thermal shock resistance of the silica fume free castables are both better than those of the silica fume containing castables ; （3） the density of the castable specimens with dense sintered alumina is 4% -6% lower than that of the castable specimens with Jhsed dense corundum so the refractories consumption of one iron runner reduces by 5% by using the tastable with dense sintered alumina, which obviously reduces the cost of refractories.展开更多
AIM: To describe our experience using a low-acceleratingdose regimen(LADR) with pegylated interferon alpha-2a and ribavirin in treatment of hepatitis C virus(HCV) recurrence. METHODS: From 2003, a protocolized LADR st...AIM: To describe our experience using a low-acceleratingdose regimen(LADR) with pegylated interferon alpha-2a and ribavirin in treatment of hepatitis C virus(HCV) recurrence. METHODS: From 2003, a protocolized LADR strategy was employed to treat liver transplant(LT) recipients with recurrent HCV at our institution. Medical records of 182 adult patients with recurrent HCV treated with LADR between 1/2003 and 1/2011 were reviewed. Histopathology from all post-LT liver biopsies were reviewed in a blinded fashion. Paired recipient and donor IL28 B status were assessed. A novel technique was employed to ascertain recipient and donor IL28B(rs12979860) Gt data using DNA extracted from archival FFPE tissue from explanted native livers and donor gallbladders respectively. The primary endpoint was SVR; secondary endpoints examined include(1) patient and graft survival;(2) effect of anti-viral therapy on liver histology(fibrosis and inflammation);(3) incidence of on-treatment development of ACR, CDR, or PCH;(4) association of recipient and donor IL28 B genotype with SVR; and(5) incidence of antiviral therapy-associated adverse events(anemia, leukopenia, thrombocytopenia, depression) and hepatic decompensation.RESULTS: The overall SVR rate was 38%(29% Gt1, 67% Gt2, 86% Gt3 and 58% Gt4). HCV Gt(P < 0.0001), donor age(P = 0.003), cytomegalovirus mismatch(P = 0.001), baseline serum bilirubin(P = 0.002), and baseline viral load(P = 0.04) were independent predictors for SVR. SVR rates were significantly higher in the recipient-CC/donor-non CC pairs(P = 0.007). Neither baseline fibrosis nor change in fibrosis stage after anti-viral therapy were associated with SVR. Fibrosis progressed in 72% of patients despite SVR. Median graft survival was 91 mo. Five-year patient survival was superior in patients who achieved SVR(97% vs 82%, P = 0.001). Pre-treatment ALP ≥ 150 U/L(P = 0.01), total bilirubin ≥ 1.5 mg/d L(P = 0.001) and creatinine ≥ 2 mg/d L(P = 0.001) were independently associated with patient survival. Only 13% of patients achieving SVR died during the followup period. Treatment discontinuation and treatmentrelated mortality occurred in 35% and 2.2% of patients, respectively. EPO, G-CSF and blood transfusion were needed in 89%, 40% and 23% of patients, respectively. Overall hospitalization rate for treatment-related serious adverse events was 21%. Forty-six(25%) of the patients were deceased; among those who died, 25(54%) were due to liver-related complications, and 4 deaths(9%) occurred while receiving therapy(2 patients experienced hepatic decompensation and 2 sepsis). CONCLUSION: LADR strategy remains relevant in managing post-LT recurrent HCV where access to DAAs is limited. SVR is associated with improved survival, but fibrosis progression still occurs.展开更多
1文献来源
Kummel S, Krocker J, Kohls A, et al. Randomized trial： Survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer [J]. Sr J Cancer, 2006,94（9） ： 1237-1244.
The electrostatic potential of electrons near the surface of static strange stars at zero temperature is studied within the frame of the MIT bag model. We find that for QCD parameters within rather wide ranges, if the...The electrostatic potential of electrons near the surface of static strange stars at zero temperature is studied within the frame of the MIT bag model. We find that for QCD parameters within rather wide ranges, if the nuclear crust on the strange star is at a density leading to neutron drip, then the electrostatic potential will be insufficient to establish an outwardly directed electric field, which is crucial for the survival of such a crust. If a minimum gap width of 200 fm is brought in as a more stringent constraint, then our calculations will completely rule out the possibility of such crusts. Therefore, our results argue against the existence of neutron-drip crusts in nature.展开更多
目的观察剂量密集型AC→T方案联合艾迪注射液对三阴性乳腺癌(triple-negative breast cancer,TNBC)新辅助化疗的近期疗效及不良反应。方法将56例TNBC患者分为对照组与治疗组,对照组26例给予剂量密集型AC→T方案治疗,治疗组30例给予剂量...目的观察剂量密集型AC→T方案联合艾迪注射液对三阴性乳腺癌(triple-negative breast cancer,TNBC)新辅助化疗的近期疗效及不良反应。方法将56例TNBC患者分为对照组与治疗组,对照组26例给予剂量密集型AC→T方案治疗,治疗组30例给予剂量密集型AC→T方案联合艾迪注射液治疗,分别对两组患者的近期疗效、骨髓抑制、肝脏及心脏酶谱、KPS评分进行比较。结果两组的近期疗效差异无统计学意义(P>0.05),对照组骨髓抑制程度高于治疗组(P<0.05)。对照组化疗后肝脏及心脏酶谱均明显升高,KPS评分则显著降低(均P<0.05),而治疗组化疗前后无显著变化(均P>0.05)。结论剂量密集型AC→T方案联合艾迪注射液治疗TNBC患者并未提高近期疗效,但能减轻化疗的副反应,提高患者的生活质量。展开更多
文摘This retrospective analysis compared standard regimen of doxorubicin, bleomycin, vin- blastine, and dacarbazine （ABVD） with the dose-dense ABVD regimen （ABVD-21） in terms of effi- cacy and toxicity. Patients who had early-stage unfavorable or advanced Hodgkin＇s lymphoma （HL） according to German Hodgkin Study Group criteria from March 1999 to February 2011 were ana- lyzed for treatment response, long-term survival and hematological toxicity. There were 85 patients in the ABVD-21 group and 118 patients in the ABVD group respectively. The complete remission rates aider completion of treatment were 92.9% and 90.7% for ABVD-21 and ABVD, respectively. During a median follow-up period of 62 months, no significant difference was found in projected 10-year progression-free survival （PFS） and overall survival （OS） rates （84.7% and 94.1% respectively for ABVD-21; 81.4% and 91.5% for ABVD）. Subgroup analyses showed that ABVD-21 was signifi- cantly better than ABVD for patients with IPS〉3 in terms of PFS and OS rates. Grade 3 to 4 leuko- penia （51.8% vs. 28.8%, P=0.001） and neutropenia （57.6% vs. 39.0%, P=0.009） were more common with ABVD-21. We were led to conclude that dose-dense ABVD did not result in better tumor con- trol and overall survival than did ABVD for early-stage unfavorable HL. However, patients at high risk, for example, with IPS〉3, may benefit from dose-dense ABVD.
文摘Chemotherapy with continuous infusion of 5-fluorouracil and cisplatin in a monthly schedule is one of the most common regimens in the treatment of advanced gastric cancer. In this study, we evaluated the efficacy and safety of a dosedense administration of this regimen in this patient population. Sixty-six consecutive patients with previously untreated histologically confirmed unresectable or metastatic gastric adenocarcinoma were treated with a 2-hour infusion of cisplatin 100 mg/m2 followed by continuous infusion of 5-fluorouracil 1000 mg/m2/day for 5 days, every 21 days. The most common grade ≥3 toxicities were fatigue (42%), nausea/vomiting (30%) and leucopenia (12%). Four patients (6%) died from treatment-related toxicity. The response rate was 35%, the median progression-free survival was 4.3 months and the median survival was 5.9 months. In light of these results, the dose-dense approach seems to offer little, if any, benefit compared with the standard regimens.
基金The project supported by the National Natural Science Foundation of China.Most part of this work was done in the period when the auther was a postdoctor at the Institute of High Energy Physics,Academia Sinica
文摘The hot dense nuclear matter is studied in the chiral σ-ω model in theformalism of thermo-field dynamics.The binding energy,pressure and effective mass ofnucleon are calculated in the level of one-loop vaccum quantum fluctuation.The tem-perature effect is found very large at high temperature and the pressure can not reachsaturation as a function of nuclear density.
文摘We study a general framework for assessing the injury probability corresponding to an input dose quantity. In many applications, the true value of input dose may not be directly measurable. Instead, the input dose is estimated from measurable/controllable quantities via numerical simulations using assumed representative parameter values. We aim at developing a simple modeling framework for accommodating all uncertainties, including the discrepancy between the estimated input dose and the true input dose. We first interpret the widely used logistic dose-injury model as the result of dose propagation uncertainty from input dose to target dose at the active site for injury where the binary outcome is completely determined by the target dose. We specify the symmetric logistic dose-injury function using two shape parameters: the median injury dose and the 10 - 90 percentile width. We relate the two shape parameters of injury function to the mean and standard deviation of the dose propagation uncertainty. We find 1) a larger total uncertainty will spread more the dose-response function, increasing the 10 - 90 percentile width and 2) a systematic over-estimate of the input dose will shift the injury probability toward the right along the estimated input dose. This framework provides a way of revising an established injury model for a particular test population to predict the injury model for a new population with different distributions of parameters that affect the dose propagation and dose estimation. In addition to modeling dose propagation uncertainty, we propose a new 3-parameter model to include the skewness of injury function. The proposed 3-parameter function form is based on shifted log-normal distribution of dose propagation uncertainty and is approximately invariant when other uncertainties are added. The proposed 3-parameter function form provides a framework for extending skewed injury model from a test population to a target population in application.
文摘A computer program MACA was developed for simulating high-dose ion implantation into amorphous solids. The topology of amorphous solids was modelled by adjusting the free flight path distribution between collisions, so that the radial distribution function will characterize the short - range order and long - range disorder of amorphous targets. A simulation example is given.
文摘Three different kinds of corundum aggregates-tabular sintered alumina, dense sintered alumina, and fused dense corundum-were introduced into the silica fume .free or silica fume containing Al2O3 -SiC - C iron runner castables to investigate their influences on the flow ability, linear change on heating, bulk density, apparent porosity, cold strength, hot modulus of rupture, therm, al shock resistance, slag resistance, oxidation resistance as well as wear resistance of Al2O3 - SiC - C iron runner castables. The results show that （ 1 ） compared with the specimens with fused dense corundum, the specimens with dense sintered alumina have equivalent installation property, slag resistance and oxidation resistance, equivalent or even higher cold modulus of rupture, cold crushing strength and hot modulus of rupture, exhibiting better thermal shock resistance and cold wear resistance ; （2） adopting bimodal alumina micropowder LISAL22RABL as well as water reducers ZX2 and ZD2 can well reduce the water requirement of silica fume free castables, solving the problem of deteriorated flow ability resulted from the lack of silica fume; since the lack of silica fume avoids the formation of low melting point liquid, the hot modulus of rupture and the thermal shock resistance of the silica fume free castables are both better than those of the silica fume containing castables ; （3） the density of the castable specimens with dense sintered alumina is 4% -6% lower than that of the castable specimens with Jhsed dense corundum so the refractories consumption of one iron runner reduces by 5% by using the tastable with dense sintered alumina, which obviously reduces the cost of refractories.
基金Supported by JTD(an employee of Mount Sinai Medical Center)in part was provided by Genentech Pharmaceuticals
文摘AIM: To describe our experience using a low-acceleratingdose regimen(LADR) with pegylated interferon alpha-2a and ribavirin in treatment of hepatitis C virus(HCV) recurrence. METHODS: From 2003, a protocolized LADR strategy was employed to treat liver transplant(LT) recipients with recurrent HCV at our institution. Medical records of 182 adult patients with recurrent HCV treated with LADR between 1/2003 and 1/2011 were reviewed. Histopathology from all post-LT liver biopsies were reviewed in a blinded fashion. Paired recipient and donor IL28 B status were assessed. A novel technique was employed to ascertain recipient and donor IL28B(rs12979860) Gt data using DNA extracted from archival FFPE tissue from explanted native livers and donor gallbladders respectively. The primary endpoint was SVR; secondary endpoints examined include(1) patient and graft survival;(2) effect of anti-viral therapy on liver histology(fibrosis and inflammation);(3) incidence of on-treatment development of ACR, CDR, or PCH;(4) association of recipient and donor IL28 B genotype with SVR; and(5) incidence of antiviral therapy-associated adverse events(anemia, leukopenia, thrombocytopenia, depression) and hepatic decompensation.RESULTS: The overall SVR rate was 38%(29% Gt1, 67% Gt2, 86% Gt3 and 58% Gt4). HCV Gt(P < 0.0001), donor age(P = 0.003), cytomegalovirus mismatch(P = 0.001), baseline serum bilirubin(P = 0.002), and baseline viral load(P = 0.04) were independent predictors for SVR. SVR rates were significantly higher in the recipient-CC/donor-non CC pairs(P = 0.007). Neither baseline fibrosis nor change in fibrosis stage after anti-viral therapy were associated with SVR. Fibrosis progressed in 72% of patients despite SVR. Median graft survival was 91 mo. Five-year patient survival was superior in patients who achieved SVR(97% vs 82%, P = 0.001). Pre-treatment ALP ≥ 150 U/L(P = 0.01), total bilirubin ≥ 1.5 mg/d L(P = 0.001) and creatinine ≥ 2 mg/d L(P = 0.001) were independently associated with patient survival. Only 13% of patients achieving SVR died during the followup period. Treatment discontinuation and treatmentrelated mortality occurred in 35% and 2.2% of patients, respectively. EPO, G-CSF and blood transfusion were needed in 89%, 40% and 23% of patients, respectively. Overall hospitalization rate for treatment-related serious adverse events was 21%. Forty-six(25%) of the patients were deceased; among those who died, 25(54%) were due to liver-related complications, and 4 deaths(9%) occurred while receiving therapy(2 patients experienced hepatic decompensation and 2 sepsis). CONCLUSION: LADR strategy remains relevant in managing post-LT recurrent HCV where access to DAAs is limited. SVR is associated with improved survival, but fibrosis progression still occurs.
文摘1文献来源
Kummel S, Krocker J, Kohls A, et al. Randomized trial： Survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer [J]. Sr J Cancer, 2006,94（9） ： 1237-1244.
基金Supported by the National Natural Science Foundation of China
文摘The electrostatic potential of electrons near the surface of static strange stars at zero temperature is studied within the frame of the MIT bag model. We find that for QCD parameters within rather wide ranges, if the nuclear crust on the strange star is at a density leading to neutron drip, then the electrostatic potential will be insufficient to establish an outwardly directed electric field, which is crucial for the survival of such a crust. If a minimum gap width of 200 fm is brought in as a more stringent constraint, then our calculations will completely rule out the possibility of such crusts. Therefore, our results argue against the existence of neutron-drip crusts in nature.
文摘目的观察剂量密集型AC→T方案联合艾迪注射液对三阴性乳腺癌(triple-negative breast cancer,TNBC)新辅助化疗的近期疗效及不良反应。方法将56例TNBC患者分为对照组与治疗组,对照组26例给予剂量密集型AC→T方案治疗,治疗组30例给予剂量密集型AC→T方案联合艾迪注射液治疗,分别对两组患者的近期疗效、骨髓抑制、肝脏及心脏酶谱、KPS评分进行比较。结果两组的近期疗效差异无统计学意义(P>0.05),对照组骨髓抑制程度高于治疗组(P<0.05)。对照组化疗后肝脏及心脏酶谱均明显升高,KPS评分则显著降低(均P<0.05),而治疗组化疗前后无显著变化(均P>0.05)。结论剂量密集型AC→T方案联合艾迪注射液治疗TNBC患者并未提高近期疗效,但能减轻化疗的副反应,提高患者的生活质量。
